

HY-117688 · 50 mg
MedChemExpress · Cat: HY-117688
Reach 3+ verified distributors
Manufacturer product page
medchemexpress.com/wj35435.html
Description
WJ35435 is a dual-targeted anticancer hybrid that induces anti-HDAC in particular HDAC1 and HDAC6 and anti-topoisomerase I activities that causes DNA damage associated with a low DNA repair capability and induces cell cycle arrest at G1- and G2-phase to apoptosis. WJ35435 induces histone H3 acetylation and phosphorylation, ?-tubulin acetylation and ?-H2AX formation to achieve anti-HDAC effect. WJ35435 is promising for research of cancer.







